Advances in treating acute myeloid leukemia

Research output: Contribution to journalArticle

Abstract

Acute myeloid leukemia (AML) arises within the bone marrow from a malignant hematopoietic progenitor cell. Though AML is still often fatal, cure rates overall continue to improve incrementally yet steadily, primarily for two reasons: first, insights into the pathogenesis of AML over the last several decades have led to the development of a relatively sophisticated classification scheme that allows more nuanced risk stratification to guide treatment choices; second, improvements in stem cell transplantation have allowed many more patients to take advantage of this highly effective therapeutic technique. Improvements in overall survival for patients with AML are expected to continue rising because of the anticipated introduction of targeted therapies into this treatment platform.

Original languageEnglish (US)
Article number96
JournalF1000Prime Reports
Volume6
DOIs
StatePublished - Oct 1 2014

Fingerprint

Acute Myeloid Leukemia
Stem Cell Transplantation
Therapeutics
Hematopoietic Stem Cells
Bone Marrow
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Advances in treating acute myeloid leukemia. / Showel, Margaret; Levis, Mark J.

In: F1000Prime Reports, Vol. 6, 96, 01.10.2014.

Research output: Contribution to journalArticle

@article{abbd34b5c4984aab8fe88633d824fc54,
title = "Advances in treating acute myeloid leukemia",
abstract = "Acute myeloid leukemia (AML) arises within the bone marrow from a malignant hematopoietic progenitor cell. Though AML is still often fatal, cure rates overall continue to improve incrementally yet steadily, primarily for two reasons: first, insights into the pathogenesis of AML over the last several decades have led to the development of a relatively sophisticated classification scheme that allows more nuanced risk stratification to guide treatment choices; second, improvements in stem cell transplantation have allowed many more patients to take advantage of this highly effective therapeutic technique. Improvements in overall survival for patients with AML are expected to continue rising because of the anticipated introduction of targeted therapies into this treatment platform.",
author = "Margaret Showel and Levis, {Mark J}",
year = "2014",
month = "10",
day = "1",
doi = "10.12703/P6-96",
language = "English (US)",
volume = "6",
journal = "F1000Prime Reports",
issn = "2051-7599",
publisher = "Faculty of 1000 Ltd",

}

TY - JOUR

T1 - Advances in treating acute myeloid leukemia

AU - Showel, Margaret

AU - Levis, Mark J

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Acute myeloid leukemia (AML) arises within the bone marrow from a malignant hematopoietic progenitor cell. Though AML is still often fatal, cure rates overall continue to improve incrementally yet steadily, primarily for two reasons: first, insights into the pathogenesis of AML over the last several decades have led to the development of a relatively sophisticated classification scheme that allows more nuanced risk stratification to guide treatment choices; second, improvements in stem cell transplantation have allowed many more patients to take advantage of this highly effective therapeutic technique. Improvements in overall survival for patients with AML are expected to continue rising because of the anticipated introduction of targeted therapies into this treatment platform.

AB - Acute myeloid leukemia (AML) arises within the bone marrow from a malignant hematopoietic progenitor cell. Though AML is still often fatal, cure rates overall continue to improve incrementally yet steadily, primarily for two reasons: first, insights into the pathogenesis of AML over the last several decades have led to the development of a relatively sophisticated classification scheme that allows more nuanced risk stratification to guide treatment choices; second, improvements in stem cell transplantation have allowed many more patients to take advantage of this highly effective therapeutic technique. Improvements in overall survival for patients with AML are expected to continue rising because of the anticipated introduction of targeted therapies into this treatment platform.

UR - http://www.scopus.com/inward/record.url?scp=84908256816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908256816&partnerID=8YFLogxK

U2 - 10.12703/P6-96

DO - 10.12703/P6-96

M3 - Article

C2 - 25374674

AN - SCOPUS:84908256816

VL - 6

JO - F1000Prime Reports

JF - F1000Prime Reports

SN - 2051-7599

M1 - 96

ER -